References
- Costigan M, Scholz J, Woolf CJ. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annu Rev Neurosci. 2009;32:1.
- Woolf CJ. What is this thing called pain?. J Clin Invest. 2010;120(11):3742.
- Scholz J, Woolf CJ. Can We Conquer Pain?. Nat. 2002;5:1062.
- Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet. 2010;9:807.
- Butera JA. Current and emerging targets to treat neuropathic pain. J Med Chem. 2007;50:2543.
- Universite d’Auvergne. Composition for the prophylactic treatment of neuropathic pain. US20140378551 (2014).
- Northwestern University. Methods of treating neuropathic pain. US20150343013 (2015).
- Kong X. Amino acids derivatives for the treatment of neuropathic pain. US20140171507 (2014).
- Bial-Portela & CA SA. Use of 5H-Dibenz/B,F/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders. US20150313910 (2015).
- Department of Health and Human Services, US . The use of(2S,6S)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S) ketamine in the treatment of depression and neuropathic pain. CA2851619 (2014).
- Apkarian Technologies LLC. Method for treating chronic neuropathic pain. US20140213621 (2014).
- GW Pharma Limited. Cannabinoids for use in the treatment of neuropathic pain. GB2524689 (2015).
- Les Laboratoires Servier. Use of 4-{3-[cishexahydrocyclopenta[C]pyrrol-2-(1H)-yl]propoxy}benzamide in the treatment of neuropathic pain. US20160051513 (2016).
- Aestus Therapeutics Inc. Methods of treating neuropathic pain with benzimidazol derivative agonist of PPARgamma. US20140024692 (2014).
- Glenmark Pharmaceuticals SA. TRPA1 antagonist for the treatment of pain associated to diabetic neuropathic pain. WO2016042510 (2016).
- OrphoMed Inc. Use of buprenorphine dimer in the treatment of peripheral neuropathic pain. US20160030881 (2016).
- Astellas Pharma Inc. Triazole derivative for use in the treatment of neuropathic pain and fibromyalgia. BR112013005532 (2016).
- The Regents of the University of California. Treating neuropathic pain with sEH inhibitors. US20150065540 (2015).
- Ruprecht-Karls-Universitat Heidelberg. Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component. WO2016050835 (2016).
- PPTM International SARL. Combination of pregabalin and meloxicam for the treatment of neuropathic pain. WO2016005897 (2016).
- University of Kentucky Research Foundation. Method of treating neuropathic pain. US20140011836 (2014).
- Metselex Inc. Prevention or attenuation of neuropathic pain or kidney injury by Tauroursodeoxycholic acid. US20140296194 (2014).
- Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional. Pharmaceutical composition combining Diosmin and Hesperidin and its use in neuropathic pain. WO2015019334 (2015).
- The Arizona Board of Regents on the behalf of the University of Arizona. Dynorphin A analogs with bradykinim receptors specificity for modulation of neuropathic pain. WO2014190313 (2014).
- Indiana University Research and Technology Corporation. Materials and method for suppressing inflammatory and neuropathic pain. US20160031945 (2016).
- Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V. Inhibitors of NOX4 expression and/or NOX4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain. US20150051264 (2015).
- INSERM (Institut National de la Sante et de la Recherche Medicale & Universite de Montpellier). Methods and compositions for treating neuropathic pain. WO2016005422 (2016).